Xenitra Sales Surge 300% in Q3 as Nutritionals Deal Anchors Turnaround
Xenitra delivers 300% sales surge in Q3 as turnaround gains momentum
Xenitra has reported Q3 FY26 sales of $8.3 million, representing growth of more than 300% compared to Q2, according to preliminary unaudited data released in the company’s quarterly sales update. The blockchain tokenised sales ecosystem operator, which specialises in FMCG, nutraceuticals and OTC medicine products across Asia, has now generated total sales exceeding $70 million since 2024. The result demonstrates the company’s turnaround strategy is delivering tangible commercial outcomes following a period of restructuring.
When big ASX news breaks, our subscribers know first
Monthly sales trajectory shows accelerating growth
The quarterly progression revealed March 2026 as the standout month, with sales surpassing $4 million AUD. Chairman Anthony Noble described this performance as representing “an almost full recovery to the annualised sales levels of FY24” — achieved with “a leaner and more focussed structure.”
| Month | Sales Performance | Significance |
|---|---|---|
| January 2026 | Quarter opening baseline | Initial recovery phase following restructuring |
| February 2026 | Sequential growth | Momentum building ahead of partnership activation |
| March 2026 | Over $4m AUD | Near-full recovery to FY24 annualised run rate |
Chairman Anthony Noble
“After a period of transition and renewal, the Company now has a solid basis from which to grow accross multiple new markets, all of which are firmly alligned to our strategy and are based in markets where the Company has a proven track record for sales and marketing excellence.”
What is a blockchain tokenised sales ecosystem?
Xenitra operates a hybrid business model combining traditional Asian distribution channels with emerging blockchain technology. The company’s platform integrates business-to-business (B2B) wholesale, retail distribution and ecommerce sales across major Asian platforms, enhanced by tokenised transaction capabilities through its OPAL token launch.
Chairman Noble described the blockchain component as “anchored in real world assets” — specifically, the FMCG and consumer goods products the company has established expertise in distributing. This Web3 integration layer sits atop proven distribution infrastructure, allowing the company to tokenise transactions and sales flows for products moving through its existing channels.
The model represents a differentiated approach in the consumer goods distribution sector, potentially offering margin expansion through blockchain-enabled efficiencies while maintaining revenue generation from traditional wholesale and retail pathways.
Nutritionals division anchors near-term revenue visibility
The $30 million strategic partnership with Rockcheck Group for Danone products served as the primary driver of Q3 sales growth. Beyond the headline offtake value, Xenitra secured approval as a supplier to the broader Rockcheck conglomerate, creating potential for additional product sales beyond the initial Danone-focused agreement.
Noble described this arrangement as providing “a solid floor to revenue” for the coming year, establishing a revenue baseline from which higher-margin divisions can build incremental contribution.
Key elements of the Rockcheck partnership:
- $30 million offtake agreement value established
- Danone products serving as initial product focus
- Broader conglomerate supplier approval achieved
- Additional accretive product sales now enabled beyond core agreement
New higher-margin divisions positioned for Q4 contribution
During Q3, Xenitra launched two additional sales channels that did not contribute materially to the quarterly result: OTC Medicines and Blockchain Tokenised sales. The OTC Medicines division was established through the Fukang acquisition, which provided both an experienced team and an established online presence in the category.
Noble noted these divisions offer “significantly higher gross margins” compared to the nutritionals wholesale business, with sales contribution expected to commence in Q4. The chairman stated the “value of this work is not reflected in this strong performance in Q3, but will begin to deliver sales in Q4.”
This timing creates a potential uplift scenario where Q4 results could reflect both sustained nutritionals revenue and initial contribution from higher-margin product categories.
The next major ASX story will hit our subscribers first
Investment thesis strengthens on multiple growth vectors
Xenitra’s Q3 result positions the company with its turnaround phase complete and multiple growth channels now operational. Noble’s statement about having “a solid basis from which to grow accross multiple new markets” reflects confidence in the platform’s scalability, supported by what the chairman described as “a proven track record for sales and marketing excellence” in Asian markets.
Active growth vectors now in place:
- Nutritionals: Anchored by $30 million Rockcheck partnership providing revenue floor
- OTC Medicines: Established via Fukang acquisition with team and online presence operational
- Blockchain Tokenised sales: OPAL token ecosystem launched, described as “a truly ground breaking and innovative new division”
- Existing distribution channels: B2B wholesale, retail and ecommerce platforms across Asia
The Q3 performance validates the restructuring programme’s effectiveness, with March sales demonstrating the company has recovered to historical revenue run rates using a more efficient operational structure. Higher-margin revenue streams remain to contribute in coming quarters, suggesting potential for margin expansion alongside top-line growth.
Don’t Miss the Next Consumer Breakthrough
Join 20,000+ investors receiving FREE breaking ASX news within minutes of release, complete with in-depth analysis. Get Consumer sector alerts delivered straight to your inbox the moment market-moving announcements drop. Click the “Free Alerts” button at Big News Blast to stay ahead on emerging opportunities.